TRAIL R2

TRAIL R2 Informations sur la molécule

Nom anglais	Tumor necrosis factor receptor superfamily member 10B	Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	10	Alias de la cible	Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
Phase de R&D la plus avancée	Approved

Nom anglais	Tumor necrosis factor receptor superfamily member 10B
Alias de la cible	Tumor necrosis factor receptor superfamily member 10B，CD262，DR5，KILLER，TRAILR2，Death receptor 5，TRAIL-R2，UNQ160/PRO186，TNFRSF10B，TNF Receptor Superfamily Member 10b，TNF-Related Apoptosis-Inducing Ligand Receptor 2，TRICK2，ZTNFR9，P53-Regulated DNA Damage-Inducible Cell Death Receptor(Killer)，Tumor Necrosis Factor Receptor-Like Protein ZTNFR9，Death Domain Containing Receptor For TRAIL/Apo-2L，Apoptosis Inducing Protein TRICK2A/2B，Apoptosis Inducing Receptor TRAIL-R2，Cytotoxic TRAIL Receptor-2，Fas-Like Protein，TRAIL Receptor 2，CD262 Antigen，KILLER/DR5，TRICK2A，TRICK2B，TRICKB，Tumor Necrosis Factor Receptor Superfamily， Member 10b
Nombre de médicaments commercialisés	1
Nombre de médicaments cliniques	10
Phase de R&D la plus avancée	Approved

TRAIL R2 Liste de produits

Attribut
Protein (6)
Bibliothèque de produits
En ligne (6)
Espèces
Human (4)Mouse (1)Cynomolgus (1)
Étiquette
His Tag (4)Fc Tag (1)His Tag & Avi Tag (1)
Marqueur
Unconjugated (4)Biotin-labeled (1)FITC Labeled (1)

Numéro de produit	Espèces	Système d'expression	Description du produit	Pré-commande/Commande
HOT TR2-H5229	Human	HEK293	Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag, low endotoxin	Ajouter au panier
HOT TR2-H5255	Human	HEK293	Human TRAIL R2 / DR5 / TNFRSF10B Protein, Fc Tag, low endotoxin	Ajouter au panier
HOT TR2-H82E6	Human	HEK293	Biotinylated Human TRAIL R2 / DR5 / TNFRSF10B Protein, Avitag™,His Tag (MALS verified)	Ajouter au panier
TR2-HF223	Human	HEK293	FITC-Labeled Human TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag	Ajouter au panier
TR2-M52H5	Mouse	HEK293	Mouse TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag	Ajouter au panier
TR2-C52H7	Cynomolgus	HEK293	Cynomolgus TRAIL R2 / DR5 / TNFRSF10B Protein, His Tag (MALS verified)	Ajouter au panier

Quantité totale6

TRAIL R2Contexte de la molécule

Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) is also known as TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2), Death receptor 5 (DR5), CD262, KILLER, is a member of the TNF-receptor superfamily, and contains an intracellular death domain. TNFRSF10B / DR-5 is widely expressed in adult and fetal tissues; very highly expressed in tumor cell lines. TRAILR2 / CD262 / DR5 is the receptor for the cytotoxic ligand TNFSF10/TRAIL. The adapter molecule FADD (a death domain containing adaptor protein) of TRAIL-R2 / TNFRSF10B recruits caspase-8 to the activated receptor. The resulting death-inducing signaling complex (DISC) performs caspase-8 proteolytic activation which initiates the subsequent cascade of caspases (aspartate-specific cysteine proteases) mediating apoptosis. CD262 / DR5 Promotes the activation of NF-kappa-B. DR5 is essential for ER stress-induced apoptosis and is regulated by p53/TP53.

TRAIL R2Alias de la molécule

TNFRSF10B,TRAILR2,TRAIL-R2,CD262,DR5,KILLER,TRICK2,ZTNFR9,TRICKB

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Dulanermin (Shanghai GeBaiDe)		Phase 3 Clinical	Shanghai Gebaide Biotechnology Co Ltd	Carcinoma, Non-Small-Cell Lung	Details
Recombinant human tumor necrosis factor-related apoptosis-inducing ligand (Shenzhen Xinpeng Biotech)		Phase 3 Clinical	Shenzhen Sinobioway Xinpeng Biomedicine Co Ltd	Neoplasms	Details
TLY-012	TLY-012	Phase 1 Clinical	Theraly Fibrosis	Fibrosis; Liver Cirrhosis; Pancreatitis; Pancreatitis, Chronic; Scleroderma, Systemic	Details
BI-905711	BI-905711	Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Cholangiocarcinoma; Gastrointestinal Neoplasms; Pancreatic Neoplasms	Details
Recombinant anti-human DR5 monoclonal antibody (Lonn Ryonn Pharma)	CTB-006	Phase 1 Clinical	Beijing Tongwei Shidai Shengwu Jishu Youxian Gongsi, Lonn Ryonn Pharma Ltd	Solid tumours	Details
Ozekibart	JCT-205; INBRX-109	Phase 1 Clinical	Inhibrx Inc	Adenocarcinoma	Details
TRAILR2/CDH3 bispecific antibody (Boehringer Ingelheim)		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Neoplasms	Details
RC-248	RC-248; RC248	Phase 1 Clinical		Solid tumours	Details
IBI-3004	IBI-3004; IBI3004	Phase 1 Clinical		Colorectal Neoplasms; Solid tumours	Details
Oba-01	Oba-01; Oba01	Phase 1 Clinical	Yantai Heyuanaidisi Biomedical Technology Co Ltd	Carcinoma, Non-Small-Cell Lung	Details

Informations sur les médicaments commercialisés

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Plus ancien nom de marque	Pays d'approbation le plus ancien	Indication la plus ancienne	Société d'approbation la plus ancienne	Date d'approbation la plus ancienne	Indication	Essai clinique
Aponermin		Approved	Beijing Shadong Biotech Co Ltd	沙艾特, Shaite	Mainland China	Multiple Myeloma	Wuhan Hiteck Biological Pharma Co Ltd	2023-11-02	Multiple Myeloma	Details